Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|April 18, 2018
Women Living With HIV and Menopause: Bridging the Data Gap
Author(s)Kelsey Fontneau, PharmD Candidate
Women living with HIV are at elevated risk for comorbidities as their life expectancy increases.
Advertisement
Individuals living with HIV now have a life expectancy that matches those without HIV and as a result, more women living with HIV (WLHIV) are experiencing menopause. However, many of these WLHIV have also fallen into a knowledge gap: practitioners who treat these patients lack experience in menopause management. Coupled with that is the fact that not only is there a serious lack of data on menopause and HIV, but many WLHIV have limited access to medical care and support.
In an attempt to bridge this gap, Post Reproductive Health published a
WLHIV are at elevated risk for comorbidities as their life expectancy increases. Both menopause and HIV infection increase the risk of cardiovascular disease, low bone mineral density, osteoporosis, and mental health diagnoses.
Menopause hormone therapy (MHT), used to treat menopause's common symptoms, and biological changes, is likely underutilized in WLHIV, because of concern of drug-drug interactions (DDIs) between MHT and antiretroviral therapy (ART). There is limited data on these DDIs; however, data on the use of ART and hormonal contraceptives may be extrapolated.
What is known is that transdermal estrogen MHT preparations are preferable in WLHIV because they are associated with a lower venous thromboembolism risk than oral preparations. Furthermore, ART pharmacokinetics do not differ between pre- and postmenopausal WLHIV, as confirmed by limited data.
In addition, HIV may be related to early onset of menopause. Studies assessing the relationship between age of menopause and HIV-related factors (ie, viral load, CD4 count, ART use) are conflicting. Evidence that vaginal symptoms of menopause, including vaginal atrophy and estrogen deficiency, increase the risk of HIV transmission or acquisition is inconclusive. No current evidence that estrogen deficiency (ie, the menopausal state) affects CD4 count or response to ART exists.
Despite these gaps, (or, perhaps, because of them) menopausal WLHIV deserve the same access to care and information as other menopausal females. Quality patient care demands adequate knowledge about symptomatology, lifestyle modifications, and treatment options. Therefore, infectious disease practitioners treating WLHIV should communicate with general practitioners to ensure the health and well-being of WLHIV transitioning through menopause.
An earlier version of this article was published on
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.